[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-354540-105":59,"doc-detail-354540-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","current-advances-in-immunotherapy-for-kras-mutant-pancreatic-cancer","Current advances in immunotherapy for KRAS-Mutant pancreatic cancer","","Pancreatic ductal adenocarcinoma (PDAC) is among the most aggressive gastrointestinal malignancies, with over 90% of cases carrying KRAS mutations that drive tumorigenesis and reshape the tumor microenvironment (TME) into an immunosuppressive “cold tumor.” This phenotype features immune-cell dysfunction, dense fibrotic stroma, and altered metabolism, contributing to resistance to immune checkpoint inhibitors (ICIs). The review details how KRAS mutations create this suppression and summarizes combination strategies pairing ICIs with chemo-, radio-, and targeted therapies, plus emerging modalities such as CAR-T, oncolytic viruses, and T-cell agonists.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/current-advances-in-immunotherapy-for-kras-mutant-pancreatic-cancer/354540/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/current-advances-in-immunotherapy-for-kras-mutant-pancreatic-cancer/354540.png","ImageObject",300,407,{"name":92,"@type":93},"awa","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":29},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why do KRAS mutations make PDAC resistant to immune checkpoint inhibitors?","Question",{"text":112,"@type":113},"KRAS-driven remodeling creates an immunosuppressive “cold tumor” TME marked by immune dysfunction, fibrotic stroma, and metabolic changes. This environment limits effective immune responses and reduces benefit from ICI monotherapy.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which combination strategies are highlighted to overcome resistance in KRAS-mutant PDAC?",{"text":117,"@type":113},"The review emphasizes multimodal combinations, including ICIs with chemotherapy or radiotherapy, and ICIs integrated with targeted therapies such as KRAS G12C/D inhibitors, PARP inhibitors, FAK inhibitors, and MEK inhibitors.",{"name":119,"@type":110,"acceptedAnswer":120},"What novel immunotherapies and delivery technologies are discussed?",{"text":121,"@type":113},"It covers CAR-T cell therapy, oncolytic viruses, and T-cell agonists. It also discusses localized delivery technologies like hydrogels, intelligent nanoparticle carriers, and oral spore systems to increase intratumoral drug concentrations while reducing systemic toxicity.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},354540,1790167743,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":29,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},3985747858093,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","Clinical and Experimental Medicine (2026) 26:285  \n[https://doi.org/10.1007/s10238-026-02201-8](https://doi.org/10.1007/s10238-026-02201-8)  \nREVIEW  \nCurrent advances in immunotherapy for KRAS-Mutant pancreatic cancer  \nMan Li1 · Xiao Wang1 · Pengen Li1 · Hongjie Gong1 · Jianbing Wu1 · Ye Mao1  \nReceived: 13 February 2026 / Accepted: 15 May 2026 © The Author(s) 2026  \nAbstract  \nPancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive gastrointestinal cancers, with over 90% of cases harboring KRAS gene mutations. These mutations not only serve as key drivers of tumorigenesis but also reshape the tumor microenvironment (TME), creating a highly immunosuppressive “cold tumor” characterized by immune cell dysfunction, a dense fibrotic stroma, and a unique metabolic state. This immunosuppressive TME contributes to the widespread resistance of PDAC to immune therapies, such as immune checkpoint inhibitors (ICIs) . This review systematically elucidates the mechanisms by which KRAS mutations shape the immune-suppressive TME, with a focus on the multimodal combination strategies developed to overcome this resistance. These strategies include combinations of ICIs with chemotherapy, radiotherapy, and targeted therapies (e.g., KRAS G12C/D inhibitors, PARP inhibitors, FAK inhibitors, MEK inhibitors), as well as explorations of novel immunotherapies like CAR-T cell therapy, oncolytic viruses, and T-cell agonists. Additionally, we discuss the potential of innovative localized drug delivery technologies, such as hydrogels, intelligent nanoparticle carriers, and oral spore systems, in enhancing intratumoral drug concentrations while reducing systemic toxicity. Despite the limited efficacy of monotherapy in immune treatment, increasing preclinical and clinical evidence suggests that well-designed combination strategies, by remodeling the TME through multiple targets, hold the promise of converting “cold tumors” into “hot tumors,” thereby restoring anti-tumor immune responses. Future breakthroughs in therapy will depend on the use of multi-omic biomarkers, including ctDNA, exosomes, and microbiomes, for precise patient stratification, guiding tailored immune combination therapies, and ultimately improving the survival outcomes of PDAC patients.  \nKeywords Pancreatic ductal adenocarcinoma · KRAS mutation · Tumor immune microenvironment · Immunotherapy · Targeted therapy · Combination therapy  \nIntroduction  \nPDAC is one of the most lethal malignancies of the digestive system, with a five-year overall survival rate of less than 10%, and an incidence rate that closely parallels its mortality rate [1] .This dismal clinical outcome is largely attributable to the insidious onset of the disease, the lack of effective methods for early diagnosis, its rapid progression, and the longstanding paucity of effective therapeutic options.  \n􀀍 Ye Mao [rayooocat111@163.com](rayooocat111@163.com)  \n1 Department of Oncology, The Second Affiliated Hospital of Nanchang University, Nanchang 330006, Jiangxi, China  \nWithin the complex molecular landscape of PDAC, KRAS mutations represent the predominant oncogenicdriver, occurring in approximately 90% of cases [1, 2].For decades, KRAS was considered an “undruggable” target because its protein structure was thought to lack suitable binding pockets for conventional small-molecule inhibitors [3] .However, recent advances have led to the successful development of inhibitors targeting the KRAS G12C mutation, providing definitive proof of the druggability ofKRASand fundamentally reshaping our understanding of its biological functions. Beyond directly promoting autonomous tumor cell proliferation, oncogenic KRAS actively remodels the TME through downstream signaling pathways. Specifically, mutant KRAS facilitates the recruitment of immunosuppressive cell populations, including myeloid-derived suppressor cells (MDSCs) and regulatory T cells (Tregs),  \ninduces functional exhaustion of effector T cells, and drives c","cbCailK30SRHibHj","https://ap.wps.com/l/cbCailK30SRHibHj","pdf",2705273,28,"English","# Introduction\n## KRAS mutations and immunosuppressive TME\n## Resistance to immune checkpoint inhibitors (ICIs)\n# Combination immunotherapy strategies\n## ICIs with chemo- and radiotherapy\n## ICIs with targeted therapies (KRAS, PARP, FAK, MEK)\n## Novel immunotherapies (CAR-T, oncolytic viruses, T-cell agonists)\n## Localized drug delivery approaches\n# Future directions","[{\"question\":\"Why do KRAS mutations make PDAC resistant to immune checkpoint inhibitors?\",\"answer\":\"KRAS-driven remodeling creates an immunosuppressive “cold tumor” TME marked by immune dysfunction, fibrotic stroma, and metabolic changes. This environment limits effective immune responses and reduces benefit from ICI monotherapy.\"},{\"question\":\"Which combination strategies are highlighted to overcome resistance in KRAS-mutant PDAC?\",\"answer\":\"The review emphasizes multimodal combinations, including ICIs with chemotherapy or radiotherapy, and ICIs integrated with targeted therapies such as KRAS G12C/D inhibitors, PARP inhibitors, FAK inhibitors, and MEK inhibitors.\"},{\"question\":\"What novel immunotherapies and delivery technologies are discussed?\",\"answer\":\"It covers CAR-T cell therapy, oncolytic viruses, and T-cell agonists. It also discusses localized delivery technologies like hydrogels, intelligent nanoparticle carriers, and oral spore systems to increase intratumoral drug concentrations while reducing systemic toxicity.\"}]","Current advances in immunotherapy for KRAS-Mutant pancreatic cancer | PDF",1790111807,71,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d15f2b191d967619e6383270f7300c29.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/5c059e649b8c10642fe8cad7f8cd0682.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1139c70214171fd4fe56400b72654ba8.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0282e5d43988cb1aa1bc2d47d4e5b947.webp",980,1301]